Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB announced promising preclinical results for CAN10, an antibody targeting IL1RAP, in vascular inflammation models. The study, published i...
Home/KnloSights/Clinical Trial Updates/Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation